Our study demonstrated that: 1) IgSF11 gene expression was elevated in high grade glioma patients, 2) IgSF11 protein was also detected in different glioma patients, 3) The high IgSF11 transcript expression in high grade gliomas was corroborated in an independent cohort, TCGA, 4) IgSF11 transcript levels positively correlated with other critical immune checkpoints, 5) Patients with elevated IgSF11 levels, exhibit immune cell infiltration but an immuno-suppressive microenvironment, and 6) Elevated expression of IgSF11 in glioma patients associated to a poor overall survival. Here, IGSF11 is linked to central nervous system cancer.